Flucloxacillin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Flucloxacillin: From Staphylococcal Infections to Conjunctivitis
One-Sentence Summary
Flucloxacillin is an anti-staphylococcal penicillin antibiotic, marketed in Australia as an oral capsule. The TxGNN model predicts it may be effective for conjunctivitis, but there are no registered clinical trials and only 1 publication (a gonococcal dacryoadenitis case report, which is not direct evidence). The prediction is currently model-driven only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report (flucloxacillin is generally used for infections caused by susceptible staphylococci) |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 0.9984 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, flucloxacillin is a penicillinase-resistant beta-lactam antibiotic with activity against susceptible Staphylococcus aureus. Bacterial conjunctivitis is sometimes caused by staphylococci, so antibacterial activity against such infections is plausible.
However, the link is weak. The only retrieved publication concerns gonococcal dacryoadenitis, caused by Neisseria gonorrhoeae, which is not typically flucloxacillin-susceptible. Flucloxacillin is also not a standard topical ocular agent, and the marketed product is an oral capsule. The high model score should be viewed as a hypothesis rather than confirmation.
Other predictions in the list (for example rheumatoid arthritis, leprosy, Prinzmetal angina and several rare genetic syndromes) have no plausible mechanistic link and are likely TxGNN model (deep learning) artefacts. They are not pursued in this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41884366 | 2026 | Case report | Case Reports in Ophthalmology | Gonococcal dacryoadenitis (lacrimal gland involvement) in the context of hyperacute bacterial conjunctivitis; not direct evidence for flucloxacillin in conjunctivitis |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10788T | Flopen Viatris | Capsule 500 mg (as sodium monohydrate) | Not available in the data compiled |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Related signals appeared in the retrieved literature, although these are case-level reports for other predicted conditions: agranulocytosis with long-term use, liver enzyme elevation, and a fatal case of Stevens-Johnson syndrome/toxic epidermal necrolysis possibly linked to flucloxacillin or doxycycline. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials, and the single publication is an unrelated gonococcal case report. Flucloxacillin is an oral agent not used topically for the eye, and the safety and indication data are incomplete.
To proceed, the following is needed:
- The approved indication text and safety information from the TGA Product Information
- Mechanism of action data (for example from DrugBank)
- Microbiological evidence of flucloxacillin susceptibility in the pathogens that cause conjunctivitis
- Clinical studies, or a review of whether a suitable ocular formulation and route are feasible
- Route compatibility assessment (oral capsule versus ocular delivery)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.